Tm Bioscience
This article was originally published in The Gray Sheet
Executive Summary
Diagnostics firm signs a co-exclusive licensing agreement for German biotech firm Epidauros' patents on a biomarker related to the P450-CYP2D6 gene. The firm will pay a signing fee and royalties to Epidauros on its P450 Tag-It tests that include the biomarker. Roche Diagnostics is the only other firm with a license for this marker, which it uses in its AmpliChip CYP450 test, cleared in 2004...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.